CN Patent

CN102921007B — 防治胰岛素抵抗和糖尿病的方法和试剂

Assigned to Shanghai Institute of Nutrition and Health of CAS · Expires 2014-12-10 · 11y expired

What this patent protects

本发明涉及防治胰岛素抵抗和糖尿病的方法和试剂。首次证实了胰岛素抵抗或糖尿病患者外周血中淀粉样蛋白或蛋白片段含量显著上升，为胰岛素抵抗和2型糖尿病的诊断提供了新的途径。并且，本发明还首次揭示了淀粉样蛋白β(Aβ)能诱导外周组织产生胰岛素抵抗，其是通过激活JAK2/STAT3-SOCS-1信号通路而实现的。因此，可以以JAK2/STAT3-SOCS-1通路或其通路蛋白作为筛选药物的靶点，研究防治或缓解胰岛素抵抗或糖尿病的药物。

USPTO Abstract

本发明涉及防治胰岛素抵抗和糖尿病的方法和试剂。首次证实了胰岛素抵抗或糖尿病患者外周血中淀粉样蛋白或蛋白片段含量显著上升，为胰岛素抵抗和2型糖尿病的诊断提供了新的途径。并且，本发明还首次揭示了淀粉样蛋白β(Aβ)能诱导外周组织产生胰岛素抵抗，其是通过激活JAK2/STAT3-SOCS-1信号通路而实现的。因此，可以以JAK2/STAT3-SOCS-1通路或其通路蛋白作为筛选药物的靶点，研究防治或缓解胰岛素抵抗或糖尿病的药物。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN102921007B
Jurisdiction: CN
Classification: —
Expires: 2014-12-10
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Institute of Nutrition and Health of CAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.